Clinical Trial Update: A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease [Phase 3]

View source ↗

Summary

A Phase 3 study comparing fixed-dose combinations of fenofibrate/simvastatin 145/20 mg and 145/40 mg with fenofibrate or simvastatin monotherapies in individual…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• FENOFIBRATE (Fenofibrate)
• Fenofibrate/Simvastatin 145/20 mg fixed-dose combination (fenofibrate/simvastatin)
• Fenofibrate/Simvastatin 145/40 mg fixed-dose combination (fenofibrate/simvastatin)
• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: Abbott | Conditions: Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2014-10-30